To assess the association between antibiotic treatment duration and treatment-related adverse events among female patients with uncomplicated urinary tract infections.
Approach:
: A retrospective study used electronic health records from Optum’s de-identified Market Clarity database covering May 2023 through March 2025.
: Eligible patients were aged 12 years or older, had symptomatic uncomplicated urinary tract infections, received an antibiotic prescription within 5 days of diagnosis and had at least 12 months of prior electronic health record activity.
: Among 57,448 patients, 17,867 (31.1%) received treatment lasting at least 8 days and 39,581 (68.9%) received treatment lasting 5 to 7 days.
: Treatment duration was categorized during a 7-day period beginning with the first antibiotic prescription. Treatment-related adverse events were assessed for up to 90 days after that period.
: Researchers used propensity score weighting to account for differences in patient characteristics. Findings were presented at IDWeek 2026.
Key Findings:
Treatment lasting at least 8 days was associated with a 20% higher overall rate of treatment-related adverse events compared with treatment lasting 5 to 7 days (rate ratio, 1.20; 95% CI, 1.09–1.32; P < 0.001).
Extended treatment was associated with higher rates of gastrointestinal events (rate ratio, 1.42; 95% CI, 1.24–1.63), genitourinary events (1.52; 95% CI, 1.25–1.84), endocrine events (1.40; 95% CI, 1.02–1.91) and hypersensitivity events (2.38; 95% CI, 1.28–4.40).
Patients receiving extended treatment were older on average, with a mean age of 55.1 years versus 52.3 years, and had more coexisting medical conditions.
Nitrofurantoin was the most commonly prescribed antibiotic, accounting for 39% of prescriptions in the extended-treatment group and 46.1% in the 5-to-7-day group.
Interpretation:
The authors associated extended antibiotic treatment with higher treatment-related adverse-event rates and emphasized aligning treatment duration with antimicrobial stewardship guidelines. The findings describe an association rather than establishing that longer treatment caused the events.
Limitations:
The retrospective observational design limits causal interpretation. Propensity score weighting accounted for measured patient-characteristic differences but does not establish equivalence between groups.
The source article does not provide absolute adverse-event rates, detailed event definitions or results by individual antibiotic.
The comparison evaluated courses lasting at least 8 days versus 5 to 7 days; it did not establish an optimal duration for each antibiotic.
GSK funded the study. Several authors were GSK employees, some reported stock ownership, and Analysis Group received GSK funding to conduct the study. One co-author also reported research support from Pfizer.
Conclusion:
Among the studied female patients, antibiotic courses lasting at least 8 days were associated with higher rates of treatment-related adverse events than courses lasting 5 to 7 days. The authors highlighted treatment-duration stewardship as a patient-safety priority.
Amoxicillin-clavulanate was not linked to lower treatment failure but was associated with a slightly higher risk of secondary infections compared with amoxicillin in adults with uncomplicated acute sinusitis.